Topics

11/13/18

Andrew H. Talal, MD, professor of medicine in the Division of Gastroenterology, Hepatology and Nutrition, has been appointed to New York Gov. Andrew M. Cuomo’s task force that will advise the state on its Hepatitis C Virus (HCV) Elimination Campaign.

4/19/18

Research led by Andrew H. Talal, MD, professor of medicine in the Division of Gastroenterology, Hepatology and Nutrition, involving hepatic pharmokinetics and pharmacodynamics was the first-place winner in the Buffalo Translational Consortium (BTC) 2017 Clinical Research Achievement Awards.

3/21/18

Medical students and residents at the Jacobs School of Medicine and Biomedical Sciences stand to benefit from a new partnership between UBMD Internal Medicine and Evergreen Health to care for patients with HIV and hepatitis C.

5/17/17

The Department of Medicine’s Division of General Internal Medicine had a strong showing at the 2017 Society of General Internal Medicine (SGIM) annual meeting with 11 research posters and one oral presentation.

5/3/17

UB researchers are developing innovative ways to better diagnose and treat hepatitis C virus (HCV) in people with substance abuse disorders.

6/9/16

Andrew H. Talal, MD, professor of medicine in the Division of Gastroenterology, Hepatology and Nutrition, has received a $7 million grant to develop an effective way to treat drug users with the hepatitis C virus (HCV).

10/20/14

Federal approval of new drugs to treat the hepatitis C virus (HCV) represents “a dramatic, positive development for patients,” says University at Buffalo liver disease expert Andrew H. Talal, MD.

8/11/14

University at Buffalo experts in the Division of Gastroenterology, Hepatology and Nutrition are contributing co-authors of HCV Next, the first multidisciplinary publication focused exclusively on the hepatitis C virus.

7/11/14

Research co-authored by Andrew H. Talal, MD, shows that injection drug users who are enrolled in a treatment program want to be educated about hepatitis C virus (HCV) and are willing to be treated.

6/24/14

A study led by Andrew H. Talal, MD, is the first to trace in real time how the drug telaprevir inhibits viral replication in the liver and clears hepatitis C virus (HCV) from the cells and plasma of infected patients.